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Abstract
Aims/hypothesis Treatment change following a genetic diagnosis of MODY is frequently indicated, but little is known about the
factors predicting future treatment success. We therefore conducted the first prospective study to determine the impact of a
genetic diagnosis on individuals with GCK-, HNF1A- or HNF4A-MODY in the UK, and to identify clinical characteristics
predicting treatment success (i.e. HbA1c ≤58 mmol/mol [≤7.5%]) with the recommended treatment at 2 years.
Methods This was an observational, prospective, non-selective study of individuals referred to the Exeter Molecular Genetic
Laboratory for genetic testing fromDecember 2010 to December 2012. Individuals from the UKwithGCK- orHNF1A/HNF4A-
MODY who were not on recommended treatment at the time of genetic diagnosis, and who were diagnosed below the age of
30 years and were currently aged less than 50 years, were eligible to participate.
Results A total of 44 of 58 individuals (75.9%) changed treatment following their genetic diagnosis. Eight individuals diagnosed
withGCK-MODY stopped all diabetes medication without experiencing any change in HbA1c (49.5 mmol/mol [6.6%] both before
the genetic diagnosis and at a median of 1.25 years’ follow-up without treatment, p = 0.88). A total of 36 of 49 individuals (73.5%)
diagnosed withHNF1A/HNF4A-MODY changed treatment; however, of the 21 of these individuals whowere beingmanaged with
diet or sulfonylurea alone at 2 years, only 13 (36.1% of the population that changed treatment) had an HbA1c ≤58 mmol/mol
(≤7.5%). These individuals had a shorter diabetes duration (median 4.6 vs 18.1 years), lower HbA1c (58 vs 73 mmol/mol [7.5% vs
8.8%]) and lower BMI (median 24.2 vs 26.0 kg/m2) at the time of genetic diagnosis, compared with individuals (n = 23/36) with an
HbA1c >58 mmol/mol (>7.5%) (or <58 mmol/mol [<7.5%] on additional treatment) at the 2 year follow-up. Overall, 64% (7/11)
individuals with a diabetes duration of ≤11 years and an HbA1c of ≤69 mmol/mol (≤8.5%) at time of the genetic test achieved good
glycaemic control (HbA1c ≤58 mmol/mol [≤7.5%]) with diet or sulfonylurea alone at 2 years, compared with no participants with a
diabetes duration of >11 years and an HbA1c of >69 mmol/mol (>8.5%) at the time of genetic diagnosis.
Conclusions/interpretation In participants withGCK-MODY, treatment cessation was universally successful, with no change in
HbA1c at follow-up. In those with HNF1A/HNF4A-MODY, a shorter diabetes duration, lower HbA1c and lower BMI at genetic
diagnosis predicted successful treatment with sulfonylurea/diet alone, supporting the need for early genetic diagnosis and
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treatment change. Our study suggests that, in individuals with HNF1A/HNF4A-MODY with a longer duration of diabetes
(>11 years) at time of genetic test, rather than ceasing current treatment, a sulfonylurea should be added to existing therapy,
particularly in those who are overweight or obese and have a high HbA1c.
Keywords Genetic testing .Glucokinase .Hepatocytenuclear factor1α .Hepatocytenuclear factor4α .Maturityonsetdiabetesof
the young . Sulfonylurea . Treatment change
Abbreviation
IQR Interquartile range
Introduction
In the UK, MODY accounts for 3.6% of diabetes cases in
individuals diagnosed younger than 30 years [1]. Diagnosis
of MODY has significant implications for diabetes manage-
ment. GCK-MODY causes asymptomatic, mild fasting
hyperglycaemia (usually 5.4–8.3 mmol/l) [5]. The glucose
level is regulated at a higher level in GCK-MODY, making
glucose-lowering treatment ineffective [6], and therefore treat-
ment is not recommended [4]. Individuals with HNF1A- or
HNF4A-MODYare optimally treated with low-dose sulfonyl-
ureas [7–10] because of an increased pancreatic insulin secre-
tory response to sulfonylureas and increased insulin sensitivity
to the insulin secreted [7].
There is a significant delay from the diagnosis of diabetes
to the correct molecular genetic diagnosis of MODY [2,
11–14]. The majority of individuals are initially misdiagnosed
with type 1 or type 2 diabetes and inappropriately treated [12,
15–20].
Current data on the success of transfer to sulfonylurea treat-
ment in individuals with HNF1A/HNF4A-MODY following
genetic diagnosis are limited and retrospective [11, 21]. In one
case, a study focused on individuals in a single centre with
expertise in monogenic diabetes [10]. There have been no
prospective studies that have assessed the success of treatment
change, glycaemic control and maintenance on recommended
treatment following genetic diagnosis in individuals with
MODY in non-specialist centres.
The aims of our study were to determine the impact of a
genetic diagnosis on diabetes treatment in UK individuals
with GCK-, HNF1A- or HNF4A-MODY, and to identify clin-
ical characteristics that predict successful management (i.e.
HbA1c ≤58 mmol/mol [≤7.5%]) with no treatment in those
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with GCK-MODYor sulfonylureas in those with HNF1A and
HNF4A-MODYat 2 years after genetic diagnosis.
Methods
Study design This was an observational, prospective, non-
selective study of all individuals with HNF1A/HNF4A- or
GCK-MODY identified from routine UK referrals to the
Exeter Molecular Genetic Laboratory for genetic testing from
December 2010 to December 2012. Ethics approval was
granted by the NRES Committee South West–Central
Bristol (REC no. 10/H0106/03). This study was part of the
UNITED (Using pharmacogeNetics to Improve Treatment in
Early-onset Diabetes) study which aimed to determine preva-
lence of monogenic diabetes in those diagnosed with diabetes
below the age of 30 years [1]. All study participants gave
informed consent (with parental consent and children’s assent
gained for those younger than 16 years, n = 9).
Individual characteristics Individuals were eligible to partici-
pate if: (1) genetic testing confirmed HNF1A-, HNF4A- or
GCK-MODY; (2) they were not on recommended treatment
at time of genetic diagnosis; and (3) they had been diagnosed
with diabetes when younger than 30 years and were younger
than 50 years at time of genetic testing. Treatment was con-
sidered ‘non-recommended’ if those with HNF1A/HNF4A-
MODYwere treated with medication other than sulfonylureas
and those with GCK-MODY were taking any diabetes
therapy.
Overall, 305 individuals referred from across the UK were
confirmed to have GCK-MODY (n = 112), HNF1A-MODY
(n = 143) or HNF4A-MODY (n = 50) within the duration of
this study. A total of 244 individuals did not meet eligibility
criteria and were not followed up: 101 were excluded on age
criteria (37 with GCK-MODY, 43 with HNF1A-MODY and
21 with HNF4A-MODY) and 143 were excluded based on
treatment criteria (63 with GCK-MODY, 61 with HNF1A-
MODYand 19 with HNF4A-MODY).
Therefore, 61 individuals fulfilled the eligibility criteria. Of
these, 58 were contactable and agreed to participate (39 with
HNF1A-MODY, 10 with HNF4A-MODY and nine with
GCK-MODY; Fig. 1). This included 11 related individuals
from five families: two parent–child pairs with HNF1A-
MODY; one family in which the mother, her son and her sister
had HNF1A-MODY; one sibling pair with HNF1A-MODY;
and one sibling pair withGCK-MODY (see electronic supple-
mentary material [ESM] Table 1). All the individuals in the
study were white, except one who was of mixed white and
East Asian ethnicity. There were 41 women. The median age
at the diagnosis of diabetes was 17 (interquartile range [IQR]
13–21] years; at the time of genetic testing median BMI was
24.8 (IQR 21.9–28.2) kg/m2, duration of diabetes 10 (IQR 2–
20) years and baseline HbA1c 59.5 (IQR 50–73) mmol/mol
(7.6% [IQR 6.7–8.8%]). At the time of genetic diagnosis, 50
individuals (86.2%) were being treated with insulin (43 with
HNF1A/HNF4A-MODY and seven with GCK-MODY) and
eight (13.8%) were taking metformin alone (six with
HNF1A/HNF4A-MODY and two with GCK-MODY). Of
those on insulin, 46 were on insulin alone and four took met-
formin in addition. The BMI for children under the age of
19 years was adjusted to the adult equivalent using the Child
Growth Foundation Reference Standards [22].
Follow-up and treatment Individuals were telephoned at base-
line (i.e. the time of the genetic test result) and at 3, 6, 12 and
24 months. Self-reported diabetes treatment was recorded.
HbA1c was measured at baseline (prior to treatment change)
and at 3, 6 and 12 months from ‘finger-prick’ blood samples
that were collected at home and posted to the Blood Sciences
laboratory at the Royal Devon and Exeter NHS Foundation
Trust. HbA1c results at 24 months were accessed from the
individual’s local laboratory. Genetic reports included a state-
ment indicating the recommended treatment for GCK-,
HNF1A- and HNF4A-MODY, but all decisions regarding di-
abetes management after genetic diagnosis were made by lo-
cal clinicians.
Statistical analysis Non-parametric tests (Mann–Whitney test
for continuous variables, χ2 or Fisher’s exact test for categor-
ical variables) were used to compare the characteristics of
treatment groups. The Wilcoxon matched-pairs signed-ranks
test was used to compare HbA1c results before and after the
genetic diagnosis. Continuous data are expressed as medians
(IQR). A p value <0.05 was considered significant. For two
individuals, a single HbA1c value was imputed assuming a
linear trend between two available HbA1c points. Analysis
was conducted using Stata/SE 14 (StataCorp, College
Station, TX, USA).
Results
A total of 44 of 58 individuals (75.9%) changed treatment
following the genetic diagnosis (Fig. 1, ESM Table 1).
Eleven of the 44 participants (25%) were younger than
18 years (four with GCK-MODY, six with HNF1A-MODY
and one with HNF4A-MODY) at the time of genetic diagno-
sis. Fourteen individuals (24.1%) did not change treatment
and were not followed-up. Reasons for continuing with the
previous treatment were pregnancy (n = 3), individual choice
(n = 5) and clinician choice (n = 5); this included individuals
with retinopathy and nephropathy or concomitant confirmed
type 1 diabetes (n = 1, GAD-antibody positive, urine C-
peptide creatinine ratio 0.12 nmol/mol) (Fig. 1).
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Eight of nine individuals with GCK-MODY (including
seven previously treated with insulin) stopped all diabetes
treatment following their genetic diagnosis, irrespective of
diabetes duration (median 1.8 [IQR 0.6–7.2] years) and BMI
(median 19.8 [IQR 17.9–22.7] kg/m2). HbA1c remained the
same at a median of 1.25 (IQR 1–2) years’ follow-up without
any treatment (49.5 [IQR 47–52] mmol/mol [6.6%, IQR 6.4–
6.9%] at the genetic diagnosis vs 49.5 [IQR 47–50.5]
mmol/mol [6.6%, IQR 6.5–6.8%] at follow-up, p = 0.88)
(ESM Fig. 1). One individual with GCK-MODY stopped in-
sulin but remained on metformin through the clinician’s
choice; however, all recorded HbA1c values were 52–
57 mmol/mol (6.9–7.4%), which are consistent with levels
seen in GCK-MODY.
A total of 36 of 49 (73.5%) individuals diagnosed with
HNF1A/HNF4A-MODY changed treatment following the ge-
netic diagnosis (Fig. 1). Of these, 21 of 36 (58%) were treated
with diet (n = 3) or sulfonylurea (n = 18) alone at 2 years.
Thirteen of these 21 individuals (62%) had HbA1c
≤58 mmol/mol (≤7.5%) at 2 years (Table 1).
We next compared the clinical characteristics of the 13
individuals (36.1%, 13/36) with HNF1A/HNF4A-MODY be-
ing managed with sulfonylurea/diet alone who achieved an
HbA1c ≤58 mmol/mol (≤7.5%) with those of the 23 individ-
uals with an HbA1c >58 mmol/mol (>7.5%) (n = 22) or
≤58 mmol/mol (≤7.5%) on additional treatment (n = 1) at
2 year follow-up (Table 1). The individuals with an HbA1c
≤58 mmol/mol (≤7.5%) on sulfonylurea/diet alone at 2 years
had a shorter diabetes duration (median 4.6 vs 18.1 years),
lower BMI (median 24.2 vs 26.0 kg/m2) and lower HbA1c
(58 vs 73 mmol/mol [7.5 vs 8.8%]) at treatment transfer com-
pared with those with an HbA1c >58mmol/mol (>7.5%) or the
single individual with an HbA1c <58 mmol/mol (<7.5%) on
additional treatment (Table 1). There was no difference in
genetic aetiology between these groups (ESM Table 1).
Those managed with sulfonylurea/diet alone at 2 years im-
proved their HbA1c from a median of 58 mmol/mol (7.5%)
pre-genetic diagnosis to 46 mmol/mol (6.4%) at 2 years (p =
0.001). This contrasted with the other group, in which HbA1c
increased (median 73 vs 77 mmol/mol [8.8 vs 9.2%]), p =
0.03) (Table 1). Individuals in the latter group who were tak-
ing sulfonylureas were on maximum recommended dose
(gliclazide 160 mg twice daily).
We also assessed the combined effect of diabetes duration
and HbA1c at genetic diagnosis on the ability to achieve good
glycaemic control with diet/sulfonylurea alone in individuals
with HNF1A/HNF4A-MODY. We divided the cohort by me-
dian diabetes duration (≤11 vs >11 years) and median HbA1c
(≤69 vs >69 mmol/mol [≤8.5% vs >8.5%]) at genetic diagno-
sis (Fig. 2). A total of 10/18 individuals (56%) with a
shorter diabetes duration achieved optimal control, compared
with 3/18 (17%) with longer diabetes duration (p = 0.03).
Unable to contact
n=3 (GCK-MODY)
44 changed treatment 14 did not change treatment
Eligible
Treatment at 
2 year follow-up
Genotype/
t reatment change 
Post genetic test
Recruitment
Treatment at 
genetic test
61 confirmed MODY patients, not on recommended treatment at 
genetic test, diagnosed at <30 years and aged <50 years
(39 HNF1A-MODY, 10 HNF4A-MODY, 12 GCK-MODY)
58 MODY patients: 
n=50 on insulin (43 HNF1A/4A-MODY, 7 GCK-MODY) 
n=8 on MF alone (6 HNF1A/4A-MODY, 2 GCK-MODY)
13 HNF1A/4A-MODY (11 insulin, 2 MF) 
1 GCK-MODY (MF)a
• 5 patient choice
• 5 clinician choice (diabetes complications)
• 3 pregnant at time of study
• 1 dual diagnosis (type 1 diabetes + HNF4A-MODY)
8 GCK-MODY
stopped treatment
36 HNF1A/4A-MODY changed 
treatment
Insulin 
n=7
MF
n=1
MF
n=5
Insulin +
MF
n=2
Insulin
n=29
No treatment
n=8
Diet 
only
n=3
SU 
only
n=18
SU +
MF 
n=6
SU +
insulin
n=3
SU + insulin +
other GLA
n=3
Insulin ± other 
(non-SU) GLA
n=3
17 3
17
31 3 3
1
1
2
2
Fig. 1 Flow chart indicating recruitment, treatment at genetic diagnosis
and treatment at 2 years after the genetic diagnosis. GLA, glucose-low-
ering agent; MF, metformin; SU, sulfonylurea. aThis individual with
GCK-MODY was initially treated with insulin and metformin but did
not stop all treatment following the genetic test
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Similarly, 10/18 (56%) with lower HbA1c at genetic diagnosis
achieved optimal control compared with 3/18 (17%) with
higher HbA1c at genetic diagnosis (p = 0.03). A total of 7 of
11 individuals (64%) with shorter diabetes duration and lower
HbA1c at genetic diagnosis achieved optimal control, while
none of the individuals (0/11) with longer duration and higher
HbA1c at genetic diagnosis achieved an HbA1c ≤58mmol/mol
(≤7.5%) with diet/sulfonylurea alone (p = 0.02). Similar re-
sults were seen for diabetes duration and BMI at genetic di-
agnosis (ESM Fig. 2).
Discussion
This national, prospective, non-selective study demonstrates
that most individuals with MODY commence the recom-
mended treatment after a genetic diagnosis has been con-
firmed. However, only 58% of individuals with HNF1A/
HNF4A-MODY were on diet or sulfonylurea alone at 2 years
and, overall, just 36% of individuals with HNF1A/HNF4A-
MODY who changed treatment achieved the good glycaemic
control (≤58 mmol/mol [≤7.5%]) needed to avoid diabetes
complications. Our study suggests that successful treatment
with diet/sulfonylurea alone was most likely in those with
HNF1A/HNF4A-MODYwho had a shorter duration of diabe-
tes, healthy BMI and lower HbA1c at the time of genetic di-
agnosis. All participants with GCK-MODY were able to stop
insulin or oral hypoglycaemic agents without deterioration in
glycaemic control, as previously shown [6]. Identifying those
with GCK-MODY is important, as all diabetes treatments can
be discontinued and follow-up is not required [2–4, 6].
Improvement in glycaemic control among individuals with
HNF1A/HNF4A-MODY is needed to prevent diabetes com-
plications. Individuals withHNF1A/HNF4A-MODYare at in-
creased, or at least the same, risk of developing diabetes-
related complications compared with those with other diabetes
subtypes [23, 24]. Our study showed that despite transfer to
the recommended treatment, only 36% of individuals
Table 1 Characteristics of individuals with HNF1A/HNF4A-MODYat genetic diagnosis and at 2 year follow-up
Characteristic HbA1c ≤58 mmol/mol (≤7.5%) on
diet/sulfonylurea alone at
2 years (n = 13)
HbA1c >58 or ≤58 mmol/mol
(>7.5 or ≤7.5%) on additional
treatment at 2 years (n = 23)
p value
At genetic diagnosis/treatment transfer
Age at diabetes diagnosis, years 18.3 (14.9–21.5) 16.3 (12.8–19.1) 0.18
Duration of diabetes, years 4.6 (1.0–8.1) 18.1 (4.0–24.9) 0.01
BMI, kg/m2 24.2 (21.7–25.3) 26.0 (24.9–30.9) 0.02
HbA1c, mmol/mol 58 (52–60) 73 (62–86) 0.005
HbA1c, % 7.5 (6.9–7.6) 8.8 (7.8–10)
Women 9 (69) 19 (83) 0.42
Treatment 0.52
Insulin 12 (92) 17 (74)
Insulin + metformin 0 2 (9)
Metformin 1 (8) 4 (17)
Genetic aetiology 1
HNF1A 11 (85) 18 (79)
HNF4A 2 (15) 5 (21)
At 2 year follow-up
HbA1c, mmol/mol 46 (43–55) 77 (67–86) <0.001
HbA1c, % 6.4 (6.1–7.2) 9.2 (8.3–10.0)
HbA1c <58 mmol/mol (<7.5%) 13 (100) 1 (4)
Treatment
Diet 1 (8) 2 (9)
Sulfonylurea 12 (92) 6 (26)
Sulfonylurea + metformin 0 6 (26)
Sulfonylurea + insulin 0 3 (13)
Sulfonylurea + insulin + other GLA 0 3 (13)
Insulin ± non-sulfonylurea GLA 0 3 (13)
Data are median (IQR) for continuous variables and n (%) for categorical variables
GLA, glucose-lowering agent
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achieved an HbA1c ≤58 mmol/mol (≤7.5%) on sulfonylurea/
diet alone. The lack of optimal glycaemic control in our study
may have resulted from clinical inertia or limited experience
among local clinicians in managing HNF1A/HNF4A-MODY
and previous advice advocating a trial of sulfonylureas even in
those with longstanding diabetes [11]. The lack of
standardised treatment guidelines for individuals needing ad-
ditional second-line therapymay also contribute to suboptimal
glycaemic control. Our results are similar, albeit lower, than
those of previous studies, which found that around 50–62% of
participants attained an HbA1c ≤58 mmol/mol (≤7.5%) with
sulfonylurea therapy alone [10, 11]. The difference in the re-
sults may be a result of differences in the duration of diabetes
at genetic diagnosis.
Progressive loss of pancreatic beta cell function is a feature
of HNF1A/HNF4A-MODY, resulting in increasing glycaemia
and increasing treatment requirements over time [25].
Successful treatment change and achieving good glycaemic
control is more likely to be achieved if the genetic diagnosis
is made early. Prompt transfer to sulfonylureas, enabling op-
timal glycaemic control soon after diabetes diagnosis, may
reduce the risk of future complications in those with
HNF1A/HNF4A-MODY, as seen with type 1 and type 2 dia-
betes [26, 27]. If individuals are transferred to optimal treat-
ment early, then it may be easier to achieve good control and
to maintain it. This is reflected by our data showing that indi-
viduals with lower HbA1c levels at genetic diagnosis are more
likely to achieve good glycaemic control at 2 years. In contrast
to this, individuals with higher HbA1c levels at genetic diag-
nosis rarely achieved good glycaemic control with sulfonyl-
ureas alone. As a consequence of these data, we now recom-
mend that a sulfonylurea should be added to existing treat-
ment, rather than replacing it, in individuals with HNF1A/
HNF4A-MODY with a longer diabetes duration (>11 years),
especially in those with higher HbA1c levels at genetic diag-
nosis and a BMI >25 kg/m2.
In this study, we found that higher HbA1c levels and BMI at
genetic diagnosis were associated with reduced success on
sulfonylurea treatment in participants with HNF1A/HNF4A-
MODY. Similar results have been seen in a previous retro-
spective study [10]. In our data, a higher BMI at genetic diag-
nosis markedly reduced the success of sulfonylurea therapy in
those with a longer duration of diabetes. This is likely to re-
flect the impact of increased insulin resistance in those with
more severe beta cell dysfunction. These data raise the ques-
tion of whether weight loss may aid glycaemic control in
individuals with HNF1A/HNF4A-MODY.
Our study has limitations. Treatment decisions were made
via local clinicians and were not standardised. We did not
collect data regarding changes in BMI over time and any
effect this had on treatment requirements, which has previous-
ly been shown to negatively affect glycaemic control [10]. It
was not appropriate to use multiple regression analysis of
factors predicting successful long-term treatment with sulfo-
nylureas alone to identify the relative contribution of each
factor because of the small size of our study. We did not
measure endogenous insulin secretion at time of genetic diag-
nosis in our participants and were therefore unable to assess its
role in treatment response. Finally, our study did not have a
large enough sample size to detect whether specific genetic
mutations had an effect on the response to treatment over and
above the strongly associated clinical features we identified.
Despite these limitations, our study provides the first national
prospective data regarding treatment change following genetic
diagnosis in non-specialised centres across the UK.
In summary, our national prospective study identified that
the majority of individuals changed treatment following a ge-
netic diagnosis of MODY. Those with GCK-MODY were
able to stop all diabetes treatment with no deterioration in
HbA1c, highlighting the significance of identifying individ-
uals with GCK-MODYas diabetes medication is unnecessary
and follow-up is not required. In participants with HNF1A/
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Fig. 2 Effect of duration of diabetes and HbA1c at genetic diagnosis on
the ability to achieve good glycaemic control with diet/sulfonylurea alone
at 2 years following genetic diagnosis in individuals with HNF1A/
HNF4A-MODY. Participants were divided into groups according to
HbA1c (≤69 or >69 mmol/mol [≤8.5% or >8.5%], n = 18 in each group)
and duration of diabetes (≤11 or >11 years, n = 18 in each group) using
the median values of the HNF1A/HNF4A-MODY cohort (n = 36). The
participant numbers in each of the groups were: HbA1c ≤69 mmol/mol
(≤8.5%) and duration ≤11 years, n = 11; HbA1c ≤69 mmol/mol (≤8.5%)
and duration >11 years, n = 7; HbA1c >69 mmol/mol (>8.5%) and dura-
tion ≤11 years, n = 7; and HbA1c >69 mmol/mol (>8.5%) and duration
>11 years, n = 11. The number of individuals who had an HbA1c
≤58 mmol/mol (≤7.5%) with diet or sulfonylurea alone at 2 years in these
four groups was n = 7, n = 3, n = 3 and n = 0, respectively
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HNF4A-MODY, only 58% were maintained on sulfonylurea/
diet alone at 2 years and just 36% of participants withHNF1A/
HNF4A-MODY who changed treatment achieved an HbA1c
≤58 mmol/mol (≤7.5%) 2 years following genetic diagnosis.
A shorter duration of diabetes, lower HbA1c level and lower
BMI at genetic diagnosis predicted successful treatment with
sulfonylurea/diet alone in participants with HNF1A/HNF4A-
MODY, supporting the need for early genetic diagnosis and
treatment change.
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